FierceBiotech12h
GSK-backed Ouro Medicines launches into T-cell engager space with $120M and a clinical-stage asset
Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...
Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease
Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...
BioSpace11h
GSK-backed Ouro Launches With $115M to ‘Reset’ the Immune System
Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...
ENDPOINTS NEWS11h
With $120M, GSK-al­lied Ouro Med­i­cines throws its hat in­to bur­geon­ing TCE ring
T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...
pharmaphorum8h
Ouro makes debut with $120m for autoimmune disease TCEs
A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...
Ouro Medicines Launches To Define The Future Of Treatment For People With Immune-Mediated Diseases
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...